Trial Profile
Retrospective study comparing the infection risk in postmenopausal rheumatoid arthritis patients treated with biologic Disease Modifying Anti Rheumatic Drugs (bDMARDs) alone or concurrent with Denosumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jul 2018
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Adalimumab; Etanercept; Rituximab
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 14 Jul 2018 New trial record
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism